Coris BioConcept : 20 years of innovation and success
Coris BioConcept develops and manufactures immunochromatographic tests allowing fast and accurate diagnosis of infectious diseases. The company was founded by Dr Thierry Leclipteux in 1996, when it was still possible to start a biotech company from scratch. After a lot of determination and support, the first employees were hired only four years later. That moment marked the take-off of the company. Today, 20 years later, Dr Leclipteux and his 30 employees are proud to look back and see how big and healthy the growth has been. Those 20 years were fueled by the ambition of a never-ending innovation spirit and a worldwide expansion.
Today, Coris BioConcept is a major player in the diagnostic field offering a wide range of effective solutions for the diagnosis of viruses, bacteria and parasites. When the company started, only two products were available: the Rotavirus and Adenovirus detection tests. Still in the top-10 selling products, these two tests are now included in a total of 50 different products available, all designed and developed in-house. This success could not be reached without continuous investment in research and development. Today, the R&D department represents 40% of the entire working team, which is quite atypical for an SME.
Since the beginning, Coris BioConcept has been increasing and sharing its technical know-how by participating in multiple national and international scientific projects, mainly financed within FP6, FP7 and H2020 framework programmes. Those collaborations combined with the product distribution in more than 60 countries all over the world position Coris BioConcept as an essential player in the diagnostic field. This global involvement motivates the company to set its goals in the development of solutions to major health concerns, such as the fight against antibiotic resistance. This main issue is dramatically evolving in the context of hospital-acquired bacterial infections. Faster diagnostic solutions are required to help clinicians rapidly adopt the most accurate antibiotic treatment. The new “RESIST” range of immunochromatography tests recently launched fulfills that purpose. The NDM-, OXA-48- and KPC-K-SeT allow a precise identification of carbapenem resistant bacteria in less time than conventional laboratory methods. Other additional tests are already under development to offer the most exhaustive set of antibiotic resistances detections.
Coris BioConcept’s challenges for the future have never been that high to maintain its position as an international standard in the infectious diagnostic field. However the company keeps in mind its core values of harmony, rigour, respect and commitment that defines its way of life.
www.corisbio.com
